New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 20, 2012
19:16 EDTHEB, WWAY, NKE, MU, RHT, RIMM, TIBXOn The Fly: After Hours Movers
UP AFTER EARNINGS: Nike (NKE), up 5%... Tibco Software (TIBX), up 4.7%... Red Hat (RHT), up 5.6%... ALSO HIGHER: Westway Group (WWAY), up 8% after an affiliate of EQT Infrastructure agreed to acquire the company for $6.70 per share... DOWN AFTER EARNINGS: Research in Motion (RIMM), down 10%... Micron Technology (MU), down 3.2%... ALSO LOWER: Hemispherx BioPharma (HEB), down 24% after Bloomberg reported that an FDA advisory panel voted against recommending approval for the company's drug Ampligen.
News For NKE;TIBX;RHT;WWAY;RIMM;MU;HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
08:58 EDTMUMicron SanDisk have positive read-through from Hynix comments, says Sterne Agee
Subscribe for More Information
08:47 EDTNKEAdidas CEO has no intention to resign despite losses to Nike, Reuters says
Subscribe for More Information
January 26, 2015
08:34 EDTHEBHemispherx reports genetic changes in Ebola may impede potential treatments
Hemispherx Biopharma announced that in a new publication in the journal mBio, scientists at the U.S. Army Medical Research Institute of Infectious Disease, or USAMRIID, Harvard University, and Massachusetts Institute of Technology, or MIT, studied genetic changes in the Ebola virus, or EBOV, circulating in West Africa and concluded that genomic drift of the EBOV over time may be sufficient to block the action of otherwise potential therapies that target EBOV genetic sequences. The types of potential drugs at risk include monoclonal antibodies and small-interfering RNA which are scheduled to be evaluated during the current outbreak. The two platform drugs of Hemispherx, Alferon N and Ampligen, both experimental therapeutics in a setting of Ebola disease, have recently both demonstrated anti-EBOV activity and have mechanisms of action which are multifaceted by working through cellular "molecular cascades" rather than by targeting viral protein or genetic sequences whose specificity is vulnerable to mutational change as reported by the research consortium on January 20. Although none of the experimental drugs have been approved by the FDA, certain of the experimental therapeutics discussed in the USAMRIID/Harvard/MIT report, are being used to treat small numbers of patients under a World Health Organization, or WHO, emergency protocol. The potential impact of genomic drift on development of therapeutics for EBOV disease has already been realized for other pathogenic human virus, such as HIV and influenza. The large genetic and antigenic diversity seen in HIV has been a "major stumbling block" for development of preventative vaccines.
January 25, 2015
17:30 EDTMUDelta Air Lines, Ford, four others could shine this year, Barron's says
Delta Air Lines (DAL), Ford (F), Discover (DFS), JPMorgan Chase (JPM), Lam Research (LRCX), and Micron Technology (MU) could all provide growth at a reasonable price this year, Barron's contends in a feature article. Reference Link
January 23, 2015
12:39 EDTNKElululemon rises after JPMorgan analyst says EPS can more than double
Subscribe for More Information
06:36 EDTNKElululemon upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded lululemon (LULU) to Overweight saying its recent field work has indicated positive traffic and demand trends while management is laying the foundation for sustainable growth. The firm raised its price target for shares to $75 from $50. The retailer of athletic apparel closed yesterday up 90c to $63.76. JPMorgan notes that its $75 price target reflects a 20% discount to peers Nike (NKE) and Under Armour (UAUA).
January 22, 2015
13:03 EDTMUAnalysts differ on SanDisk after Apple loss clips outlook
Subscribe for More Information
January 21, 2015
17:50 EDTMUSanDisk reverses in after hours to down 6% after guidance
SanDisk peer Micron is trading down over 1% in the after hours.
January 20, 2015
08:25 EDTMUMicron upgraded to Positive at Susquehanna
Subscribe for More Information
06:47 EDTMUMicron upgraded to Positive from Neutral at Susquehanna
January 16, 2015
16:36 EDTMUMarket finishes week lower on continued oil, global growth worries
Subscribe for More Information
09:37 EDTMUActive equity options trading
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use